Generalized Tonic-Clonic Seizures Treatment & Management
- Author: David Y Ko, MD; Chief Editor: Selim R Benbadis, MD more...
A number of antiepileptic drugs (AEDs) are used for the treatment of generalized tonic-clonic seizures. The choice of drug should be tailored to the individual patient and to the epilepsy syndrome, not to the seizure type only.
Valproic acid is considered the agent of first choice for patients who have multiple seizure types, including generalized tonic-clonic seizures (except in female patients with reproductive capability), since it treats a broad spectrum of seizure types, including myoclonic seizures. The unblinded, randomized, controlled Standard Antiepileptic and New Antiepileptic Drug (SANAD) study on the effectiveness of valproate, lamotrigine, or topiramate for generalized and unclassifiable epilepsy supported the primacy of valproate.
Phenytoin and carbamazepine are reasonable second options among the older group of AEDs. However, the newer medications (eg, lamotrigine, topiramate, zonisamide, levetiracetam) tend to work as well if not better and have better side-effect profiles, especially regarding long-term side effects. Phenobarbital is still used by many neurologists, though its adverse cognitive effects have led to a decline in its use.
For refractory generalized epilepsy, felbamate also is used as an agent of last resort and is very effective. The adverse effects of felbamate necessitate very careful monitoring of blood counts and liver function tests.
Perampanel is approved as adjunctive treatment for primary generalized tonic-clonic seizures in adults and children aged 12 years or older.
Certain AEDs are enzyme inducers and decrease the levels of oral contraceptive agents. Warn patients of this, and advise them to use additional contraceptive precaution while on enzyme-inducing agents such as phenytoin, carbamazepine, and phenobarbital.
The older first-generation AEDs (eg, phenytoin, carbamazepine, phenobarbital, valproic acid) are all known teratogenic agents.
Vagus Nerve Stimulation
The US Food and Drug Administration (FDA) has approved vagus nerve stimulation (VNS) only for the treatment of partial seizures. Open-label VNS registry results have also shown that some patients with generalized tonic-clonic seizures respond well. In many years of clinical use of VNS, many patients with primary generalized seizures have had seizure reduction.
No other surgical option exists for pure generalized tonic-clonic seizures. Patients must be carefully evaluated and may necessitate video-EEG because some partial seizures with quick secondary bilateral synchrony may be labeled as primary generalized tonic-clonic.
A ketogenic diet can be tried to improve seizure control in younger patients whose condition is refractory. The ketogenic diet was developed at the Mayo Clinic and Johns Hopkins Institute, and it was based on the observation that seizures improved during periods of starvation. Studies have shown a substantial reduction in seizure frequency in 50% of patients placed on the diet.
The exact mechanism by which this diet works is not known. The diet typically contains a fat-to-carbohydrate ratio of 4:1. This diet produces a ketotic state but provides adequate calories for nutrition from proteins and fat.
The ketogenic diet is used for intractable epilepsy, especially in childhood. It is less commonly prescribed for adults because the diet, being very restrictive, is very difficult to maintain. In adults, a high-protein diet is being studied.
Adverse effects are mainly gastrointestinal and include bloating, constipation, renal stones, and bone and weight loss. Urinary ketones are checked daily and need to be greater than 4+ (80-160 mg/dL.
In general related to diet, avoid excessive amounts of stimulants such as energy drinks.
Driving is restricted if patients are still having seizures as per particular state laws. In addition, common-sense restrictions for patients with epilepsy should be followed, such as not operating dangerous equipment, not swimming alone, and not taking baths unsupervised, among others.
Walczak TS, Leppik IE, D'Amelio M, Rarick J, So E, Ahman P, et al. Incidence and risk factors in sudden unexpected death in epilepsy: a prospective cohort study. Neurology. 2001 Feb 27. 56(4):519-25. [Medline].
Elzawahry H, Do CS, Lin K, Benbadis SR. The diagnostic utility of the ictal cry. Epilepsy Behav. 2010 Jul. 18(3):306-7. [Medline].
Morrell MJ. Differential diagnosis of seizures. Neurol Clin. 1993 Nov. 11(4):737-54. [Medline].
Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet. 2007 Mar 24. 369(9566):1016-26. [Medline]. [Full Text].
Peters DH, Sorkin EM. Zonisamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy. Drugs. 1993 May. 45(5):760-87. [Medline].
Glauser T, Kluger G, Sachdeo R, Krauss G, Perdomo C, Arroyo S. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology. 2008 May 20. 70(21):1950-8. [Medline].